Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 825) with type 2 diabetes and hypertension (mean seated systolic blood pressure [SBP] 130–159 mmHg and diastolic blood pressure [DBP] 80–99 mmHg) were randomized (double blind) to 10 mg or 25 mg empagliflozin or placebo once daily for 12 weeks. RESULTS: At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP (ambulatory blood pressure monitoring [ABPM]) was −3.44 mmHg (95% CI −4.78, −2.09) with 10 mg empagliflozin and −4.16 mmHg (−5.50, −2.83) with 25 mg empagliflozin (both P < 0.001). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP (ABPM) was −1.36 mmHg (95% CI −2.15, −0.56) with 10 mg empagliflozin and −1.72 mmHg (95% CI −2.51, −0.93) with 25 mg empagliflozin (both P < 0.001). Changes in office BP were consistent with ABPM. Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was −0.62% (95% CI −0.72, −0.52) (−6.8 mmol/mol [95% CI −7.9, −5.7]) with 10 mg empagliflozin and −0.65% (95% CI −0.75, −0.55) (−7.1 mmol/mol [95% CI −8.2, −6.0]) with 25 mg empagliflozin (both P < 0.001). Empagliflozin was well tolerated. One patient on placebo and one patient on 10 mg empagliflozin reported events consistent with volume depletion. CONCLUSIONS: Empagliflozin was associated with significant and clinically meaningful reductions in BP and HbA1c versus placebo and was well tolerated in patients with type 2 diabetes and hypertension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EMPA-REG BP trial, empagliflozin reduced mean 24 hour ambulatory systolic BP by approximately 3-4 mmHg after 12 weeks, 16 with consistent reductions irrespective of the number of background BP lowering drugs.17”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [16]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · cited 1×
“Randomized controlled trials have shown reductions in major cardiovascular events when SBP was lowered to ,150 mmHg and DBP was lowered to # 85 mmHg in patients with diabetes (23,24).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Cited by
Items 201–300 of 505
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
Matthews, J. R., Herat, L. Y., Schlaich, M. P., & Matthews, V. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814243 · Cited by 26
“In human studies, both Empagliflozin (EMPA) [37] and Dapagliflozin (DAPA) [38] were associated with significant reductions in blood pressure in patients with diabetes compared with placebo.”
Tanaka, H., & Hirata, K. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9668-1 · Cited by 26
Sodium glucose cotransporters inhibitors in type 1 diabetes
Dellepiane, S., Nasr, M. B., Assi, E., Usuelli, V., Letizia, T., D’Addio, F., Zuccotti, G., & Fiorina, P. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.018 · Cited by 26
Fu, M., Yu, J., Chen, Z., Tang, Y., Dong, R., Yang, Y., Luo, J., Hu, S., Tu, L., & Xu, X. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111149 · Cited by 26
Younis, F. M., Leor, J., Abassi, Z. A., Landa, N., Rath, L., Hollander, K. S., Naftali‐Shani, N., & Rosenthal, T. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418763808 · Cited by 26
Böhm, M., Fitchett, D., Ofstad, A. P., Brueckmann, M., Kaspers, S., George, J. T., Zwiener, I., Zinman, B., Wanner, C., Marx, N., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002492 · Cited by 25
“The increased glucosuria is accompanied by sodium and water elimination and an expected reduction in office blood pressure (BP) [4] and of 24-hour ambulatory BP [5] in both dippers and nondippers [6], which appears to be a class effect of all SGLT2 inhibitors [7].”
BackgroundThe Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Loutradis, C., Papadopoulou, E., Angeloudi, E., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191029111713 · Cited by 25
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 25
Yoosuf, B. T., Muhammed Favas, K. T., Spoorthy, D. P., Saini, A., Garg, P., Medenica, S., Dutta, P. R., & Bansal, D. (2025) · Endocrine · doi:10.1007/s12020-025-04393-7 · Cited by 24
Timely and individualized heart failure management: need for implementation into the new guidelines
Abdin, A., Bauersachs, J. K., Frey, N., Kindermann, I., Link, A., Marx, N., Lainščak, M., Slawik, J., Werner, C. M., Wintrich, J., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01867-2 · Cited by 24
“Since SGLT2 inhibitors also lower blood pressure in hypertensive patients [13], there was concern that SGLT2 inhibitors also lower blood pressure in HF to a range that leads to intolerance [14].”
BackgroundGallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 24
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes
Neeland, I. J., Salahuddin, U., & McGuire, D. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1135900 · Cited by 24
“001).[30] Reductions in blood pressure were not associated with increases in pulse rate (suggesting”
BackgroundTsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258055 · Cited by 24
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension
Sanidas, E. A., Papadopoulos, D. P., Hatziagelaki, E. E., Grassos, C. A., Velliou, M., & Barbetseas, J. D. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz157 · Cited by 24
Beal, B. A., Schutte, A. E., & Neuen, B. L. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01281-1 · Cited by 23
“Recent studies have shown only modest reductions in nighttime systolic and diastolic blood pressures of approximately − 2.6 mmHg and − 1.5 mmHg [5, 8–10, 12, 13].”
InfluentialChen, L., Xue, Q., Yan, C., Tang, B., Wang, L., Zhang, B., & Zhao, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1256548 · Cited by 23
Gawryś, O., Kala, P., Sadowski, J., Melenovský, V., Sandner, P., & Červenka, L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177175 · Cited by 23
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
Steen, O., & Goldenberg, R. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.241 · Cited by 23
Loutradis, C., Papadopoulou, E., Theodorakopoulou, M. P., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0514 · Cited by 23
Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels
Seo, M. S., Jung, H. S., An, J. R., Kang, M., Heo, R., Li, H., Han, E., Yang, S., Cho, E.-H., Bae, Y. M., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115153 · Cited by 23
Hasan, A., & Hasan, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910842 · Cited by 23
Giaccari, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13814 · Cited by 23
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 22
You, Y., Zhao, Y., Chen, M., Pan, Y., & Luo, Z. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01182-y · Cited by 22
“These findings have important clinical implications, suggesting the potential utility of SGLT2 inhibitors as adjunctive therapy for hypertension management in patients with type 2 diabetes [14, 43].”
BackgroundSuvarna, V. R., Gupta, S., Shaikh, S. S., Joshi, P., & Bhure, S. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_517_16 · Cited by 22
“Results in Indian subgroup are consistent with previous reports where empagliflozin monotherapy displayed a lack of hypoglycemia.[12,22] Significantly less number of patients required rescue therapy in both doses of empagliflozin compared to placebo supports the fact that no severe hypoglycemia were encountered.”
ResultCardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
Woo, V. C. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.004 · Cited by 22
Jung, S., Bosch, A., Kannenkeril, D., Karg, M. V., Striepe, K., Bramlage, P., Ott, C., & Schmieder, R. E. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz078 · Cited by 22
Hasan, A., Menon, S. N., Zerin, F., & Hasan, R. (2021) · Heliyon · doi:10.1016/j.heliyon.2022.e09503 · Cited by 22
“Dapagliflozin treatment was reported to lower systemic blood pressure [9, 11, 12, 16, 42], which may reduce the risk of death from cardiovascular diseases [11].”
BackgroundEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Anderson, J. E., Wright, E. E., & Shaefer, C. F. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0211-x · Cited by 22
“To look at this group specifically, empagliflozin has also been studied in a dedicated trial in patients with hypertension in addition to T2DM [38].”
BackgroundFeng, C., Minxiang, W., Chen, Z., Yu, X., Nie, Z., Zhao, Y. C., & Bao, B. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02112-6 · Cited by 22
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Kuchay, M. S., Farooqui, K. J., Mishra, S. K., & Mithal, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_479 · Cited by 22
Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
Салухов, В. В., & Demidova, T. Y. (2016) · Diabetes Mellitus · doi:10.14341/dm8216 · Cited by 21
“Studies evaluating daily BP profiles have revealed that empagliflozin lowers BPsyst during the entire day, but at night, its hypotensive effects are slightly lower [31].”
BackgroundEMPA-REG OUTCOME: The Cardiologist's Point of View
Pham, S. V., & CHILTON, R. J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.011 · Cited by 21
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
Thompson, G., & Hershon, K. S. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s100288 · Cited by 21
“001 for both).(27) One patient on placebo and one patient on empagliflozin 10 mg reported events consistent with volume depletion.”
InfluentialYuan, T., Liu, S., Dong, Y., Fu, Y., Tang, Y., & Zhao, W. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00600-9 · Cited by 21
Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Mittermayer, F., Caveney, E. J., OLIVEIRA, C. D. F., Fleming, G. A., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160413115655 · Cited by 20
Luconi, M., Raimondi, L., Franco, A. D., & Mannucci, E. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.09.001 · Cited by 20
Pozo, L., Bello, F. O., Suárez, A., Ochoa-Martinez, F. E., Mendez, Y. H., Chang, C., & Surani, S. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.291 · Cited by 20
Kim, G. S., Park, J. H., & Won, J. C. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.2.106 · Cited by 20
Yan, C., Thijs, L., Cao, Y., Trenson, S., Zhang, Z., Janssens, S. P., Staessen, J. A., & Feng, Y. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14791 · Cited by 20
Managing Hyperkalemia in the Modern Era: A Case-Based Approach
Massicotte‐Azarniouch, D., Canney, M., Sood, M. M., & Hundemer, G. L. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.04.016 · Cited by 19
FITCHETT, D. H. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.40 · Cited by 19
Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
Woo, V. C. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12720 · Cited by 19
The role of empagliflozin in the management of type 2 diabetes by patient profile
Davis, S. N., & Hedrington, M. S. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s71762 · Cited by 19
Ünal, İ., Cansız, D., Beler, M., Sezer, Z., Güzel, E., & Emekli‐Alturfan, E. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148536 · Cited by 18
Extra‐glycaemic properties of empagliflozin
Solini, A. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2666 · Cited by 18
“8 mm Hg with 25 mg in the sitting SBP, after correction for placebo [36].”
EMPA-REG OUTCOME: The Cardiologist's Point of View
Pham, S. V., & CHILTON, R. J. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.006 · Cited by 18
Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor?
Pickup, L. C., Radhakrishnan, A., Townend, J., & Ferro, C. J. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000535 · Cited by 18
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage
Upadhya, B., Kozak, P. M., Stacey, R. B., & Vasan, R. S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01166-9 · Cited by 18
Yang, Y., Min, K. W., Park, S., Kim, K., Yu, J. M., Hong, E., Cho, S., Won, K. C., Kim, Y. H., Oh, S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15080 · Cited by 18
“Enavogliflozin showed additional benefits of weight reduction and a decrease in blood pressure, which were consistently observed in previous studies on other SGLT2 inhibitors.(4-8) Comparing the effects of SGLT2 inhibitors on weight reduction after a 12-week treatment, the weight reduction of 1.”
BackgroundResultLioudaki, E., Androulakis, E. S., Whyte, M., Stylianou, K., Daphnis, E., & Ganotakis, E. S. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6724-3 · Cited by 18
“001 vs placebo for both doses) at week 12 [18].”
BackgroundAlkabbani, W., Pelletier, R., & Gamble, J. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab052 · Cited by 18
Iqbal, F., Shuja, M. H., Azam, L., Amjad, M., Manjee, K. Z., Ramzan, H., Sharif, T., Shoaib, A., Tahir, A., Kumar, S., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.001 · Cited by 17
The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension
Ferdinand, K. C., Harrison, D. E., & Johnson, A. E. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.12.008 · Cited by 17
Cardiovascular benefit of SGLT2 inhibitors
Mohebi, R., & Januzzi, J. L. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1993439 · Cited by 17
“In two similar studies, treatment with empagliflozin led to meaningful reduction in blood pressure [98,99].”
ResultWilliams, J. M., Murphy, S., Wu, W., Border, J. J., Fan, F., & Roman, R. J. (2022) · GeroScience · doi:10.1007/s11357-022-00610-7 · Cited by 17
DAILEY, G. E. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12278 · Cited by 17
“However, a Phase 3 trial that specifically investigated empagliflozin in patients with T2DM and hypertension (mean seated office SBP 130–159 mmHg and DBP 80–99 mmHg) has been reported (NCT01370005).(23) The primary endpoints included changes from baseline in mean HbA1c and 24-h SBP (using 24-h ambulatory BP measuremen…”
BackgroundMethodTamura, K., Wakui, H., Azushima, K., Uneda, K., & Umemura, S. (2016) · Hypertension Research · doi:10.1038/hr.2016.1 · Cited by 17
Dai, X., Luo, Z.-C., Zhai, L., Zhao, W., & Huang, F. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0399-z · Cited by 17
Kuriyama, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1673-0 · Cited by 17
Kashiwagi, A., Shestakova, M. V., Ito, Y., Noguchi, M., Wilpshaar, W., Yoshida, S., & Wilding, J. P. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00699-8 · Cited by 17
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
Suzuki, Y., Kaneko, H., Okada, A., Komuro, J., Fujiu, K., Takeda, N., Morita, H., Ako, J., Nishiyama, A., Yano, Y., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01649-z · Cited by 16
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
Davis, S. N., & Munir, K. M. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s77754 · Cited by 16
“40 mmHg in the empagliflozin 10 mg/d and 25 mg/d arms, respectively).(27) Placebo-subtracted reductions in seated office blood pressure were similar to ambulatory monitoring.”
Zhang, F., Cao, X., Zhao, C., Chen, L., & Chen, X. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02719-0 · Cited by 16
“Beyond lowering glucose, EMPA exerts a favorable effect on a series of non-glycemic effects, including causing modest reductions in body weight and blood pressure [24], and providing some cardiovascular and renal protection [25].”
BackgroundMorita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M. E., Azushima, K., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14976 · Cited by 16
SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Lukic, N., Mačvanin, M., Gluvic, Z. M., Rizzo, M., Radak, D. J., Suri, J. S., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673251493231011192520 · Cited by 16
A review of chemical therapies for treating diabetic hypertension
Sarafidis, P. A., Alexandrou, M. E., & Ruilope, L. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1328054 · Cited by 16
Mosleh, W., Sharma, A., Sidhu, M. S., Page, B. J., Sharma, U. C., & Farkouh, M. E. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6729-y · Cited by 16
Sorice, G. P., Cinti, F., Leccisotti, L., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Cocchi, C., Capece, U., Ferraro, P. M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01083-1 · Cited by 16
“Throughout the trial the investigators will adjust glucose-lowering therapy at their discretion to achieve the best obtainable glycemic control based on patient conditions (standard of care), with the use of any approved medicine, with the sole exception of SGLT-2is and pioglitazone.”
ResultInfluentialSodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
Xiao, L., Nie, X., Cheng, Y., & Wang, N. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07216-9 · Cited by 16
“72 mmHg changes in diastolic BP, respectively [17].”
BackgroundJacob, L., Waehlert, L., & Kostev, K. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815607860 · Cited by 15
“Interestingly, such effects on heart rate and blood pressure are also found with GLP-1 receptor agonists(35,36) and SGLT2 inhibitors.(37,38) By contrast, a controversial study has demonstrated that the unadjusted risk of cardiovascular mortality with sulfonylureas monotherapy is 3.”
BackgroundNew and emerging cardiovascular and antihypertensive drugs
Chrysant, S. G., & Chrysant, G. S. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1810232 · Cited by 15
“[39], is a randomized, double-blind, placebo-controlled study of 825 patients with T2DM and hypertension randomized to”
BackgroundInfluentialLiu, S.-C., Lee, C.-C., Chuang, S., Sun, F., & Zeng, Y.-H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.001 · Cited by 15
Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin
Aronson, R. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1027185 · Cited by 15
Using adult stem cells to monitor endothelial dysfunction in diabetes mellitus
Jain, R., Awal, H. B., & Sen, S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107588 · Cited by 15
Wu, Q., Liao, C., He, M., Li, C., Zou, F., Hu, L., Wei, Y., & Zhang, W. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13521 · Cited by 15
The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Tilinca, M. C., Tiucă, R. A., Ţilea, I., & Varga, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121249 · Cited by 15
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.07.008 · Cited by 15
Zhao, Q., Pan, Y., Xiong, Y., Xu, P., Sun, Q., Yin, H.-M., & Xue, F. (2024) · ACS Omega · doi:10.1021/acsomega.3c09922 · Cited by 14
Zheng, R., Song, W., Lu, J. L., Yuan, M., Sun, X., & Lu, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02600-3 · Cited by 14
“Notable antihypertensive effects were observed with canagliflozin [14, 16], dapagliflozin [38], and empagliflozin [39], while other antidiabetic agents, such as exenatide [40] and liraglutide [41], do not lower blood pressure.”
Yang, S., Hu, Q., Liu, K., Xiao, B., Zhang, B., & Su, N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1551390 · Cited by 14
Kashiwagi, A., Yoshida, S., Kawamuki, K., Nakamura, I., Kazuta, K., Ueyama, E., Takahashi, H., Akiyama, N., Kondo, Y., & Ogihara, T. (2016) · Diabetology International · doi:10.1007/s13340-016-0283-x · Cited by 14
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Kameda, R., Cho, K. Y., Nomoto, H., Nakamura, A., Omori, K., Nagai, S., Sachiko, E., Kawata, S., Takeuchi, J., Kameda, H., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109069 · Cited by 14
Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
Kao, T., & Huang, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1086672 · Cited by 14
“(8) RCT Empagliflozin 10 mg/d or 25 mg/d DM, intact renal function 24-h ambulatory BP 10 mg/d: ASBP 3.”
BackgroundKato, K., Suzuki, K., Aoki, C., Sagara, M., Niitani, T., Wakamatsu, S., Yanagi, K., & Aso, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1317748 · Cited by 14
“The EMPA-REG outcome trial indicated a consistent decrease of 3–6 mmHg in the SDP [34].”
Feng, Q., Wu, M., & Mai, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1482918 · Cited by 13
The effect of SGLT2 inhibitors on cardiovascular events and renal function
Imprialos, K. P., Stavropoulos, K., Doumas, M. N., Karagiannis, A. I., & Athyros, V. G. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1370371 · Cited by 13
Li, J., Zhu, C., Liang, J., Hu, J., Liu, H., Wang, Z., Guan, R., Chow, J., Yan, S., Li, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303694 · Cited by 13
Yadav, J., Ahsan, F., Panda, P., Mahmood, T., Ansari, V. A., & Shamim, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998271026231127051545 · Cited by 13
Short commentary on empagliflozin and its potential clinical impact
Hinnen, D. A. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815578599 · Cited by 13
“com significant and clinically relevant improvements in glycemic control in patients with T2DM versus placebo [Häring et al. 2013, 2014; Kovacs et al. 2013; Roden et al. 2013; Barnett et al. 2014; Tikkanen et al. 2015], as measured by the change in the level of glycated hemoglobin (HbA1c) (Table 1).”
BackgroundCebada, A. B., Nattero‐Chávez, L., Díaz, S. A., Escobar-Morreale, H. F., & Luque‐Ramírez, M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0316 · Cited by 13
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis
Ceasovschih, A., Balta, A., Aldeen, E. S., Bianconi, V., Barkas, F., Şener, Y. Z., Jakubová, M., Yılmaz, M. B., Banach, M., Șorodoc, L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101061 · Cited by 12
Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.07.029 · Cited by 12
Management of Hypertension in Diabetic Kidney Disease
Colbert, G. B., Elrggal, M. E., Gaddy, A. R., Madariaga, H. M., & Lerma, E. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216868 · Cited by 12
SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution
Tran, K. C., & Hiremath, S. S. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa100 · Cited by 12
What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Khan, M. S., & Vaduganathan, M. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01347-3 · Cited by 12
Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Dimova, R. B., & Tankova, T. I. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1298-4205 · Cited by 12
Novel approaches for treating hypertension
Freeman, A. J., Vinh, A., & Widdop, R. E. (2017) · F1000Research · doi:10.12688/f1000research.10117.1 · Cited by 12
“In high-risk cardiovascular patients with type 2 diabetes, empagli-flozin, added to standard care, lowered the rate of the primary composite cardiovascular outcome and of death from any cause 34 and reduced blood pressure versus placebo in patients with type 2 diabetes and hypertension 35 .”
BackgroundDiabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas
Brooks, L. K., Kalyanaraman, N., & Malek, R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.10.033 · Cited by 12
Metadata
- Authors
- Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J.
- Affiliations
- Helsinki University Hospital (FI)
- Boehringer Ingelheim (Finland) (FI)
- Boehringer Ingelheim (Germany) (DE)
- inVentiv Health Clinical (CA)
- Corresponding author
- Tikkanen, Ilkka
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-30
- Volume
- 38
- Issue
- 3
- Pages
- 420-428
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2138173919
- Cited by
- 468
- References
- 35
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 27 · 2023: 41 · 2022: 39 · 2021: 38 · 2020: 41 · 2019: 50 · 2018: 44 · 2017: 52 · 2016: 53 · 2015: 31 · 2014: 3
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, type 2 diabetes, hypertension, blood pressure reduction, SGLT2 inhibitors, ambulatory blood pressure monitoring, glycemic control, HbA1c, tolerability, adverse events, dose comparison, antihypertensive therapy, renin-angiotensin system blockade
- MeSH terms
- Analysis of Variance, Antihypertensive Agents, Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Administration Schedule, Female, Glucosides, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Treatment Outcome, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.